1-o-hexadecyl-2-n-methylcarbamylphosphatidylcholine has been researched along with Leukemia in 1 studies
1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine: biologically active analog of PAF; structure given in first source
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using murine erythroleukemia cells (MELCs) as the model, we found that WEB-2086, a triazolobenzodiazepine-derived PAF antagonist originally developed as an anti-inflammatory drug, induces a dose-dependent inhibition of MELC growth and hemoglobin accumulation as a result of a true commitment to differentiation." | 1.31 | Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. ( Bianchi, L; Cellai, C; Della Malva, N; Laurenzana, A; Paoletti, F; Vannucchi, AM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cellai, C | 1 |
| Laurenzana, A | 1 |
| Vannucchi, AM | 1 |
| Della Malva, N | 1 |
| Bianchi, L | 1 |
| Paoletti, F | 1 |
1 other study available for 1-o-hexadecyl-2-n-methylcarbamylphosphatidylcholine and Leukemia
| Article | Year |
|---|---|
Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Differentiation; Cell Division; Dose-Response Relatio | 2002 |